Chronic obstructive pulmonary disease and comorbid cardiovascular disease: in the context of guidelines

Cover Page

Cite item

Full Text

Abstract

The article presents a modern view on chronic obstructive pulmonary disease (COPD) and comorbid cardiovascular disease, the epidemiology is also discussed. The influence of comorbid disease on exacerbation development, prognosis and outcomes is demonstrated. Possible pathogenesis that contributes to high rate of comorbid cardiovascular disease development in patients with COPD and also to synergism in their development is presented. With regard to actual clinical guidelines the advances in COPD patients with comorbid cardiovascular disease management and treatment are discussed.

About the authors

O. D Ostroumova

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: ostroumova.olga@mail.ru
д-р мед. наук, проф. каф. факультетской терапии и профболезней, проф. каф. клин. фармакологии и пропедевтики внутренних болезней 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A. I Kochetkov

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: ak_info@list.ru
канд. мед. наук, ассистент каф. факультетской терапии и профболезней 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD 2017. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
  2. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis 2015; 10: 95-109. doi: 10.2147/COPD.S54473
  3. Chatila W.M, Thomashow B.M, Minai O.A et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac So 2008; 5 (4): 549-55.
  4. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive disease. Ann Med 2013; 45 (3): 291-300.
  5. Чазова И.Е., Чучалин А.Г., Зыков К.А. и др. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013; 1: 5-34.
  6. Farsang С, Kiss I, Tykarski A, Narkiewicz K. Treatment of Hypertension in Patients With Chronic Obstructive Pulmonary Disease (COPD) Update on Hypertension Management in COPD. Scientific Newsletter. 2016, 17, nr. 62. http: //www.eshonline.org/esh-content/uploads/2016/06/Treatment-of-Hypertension-in-Patients-With-Chronic-Obstructive-Pulmonary-Disease-COPD.pdf
  7. Anthonisen N.R, Connett J.E, Enright P.L, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166 (3): 333-9.
  8. Kim S-H, Park J-H, Lee J-K et al. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine. 2017; 96 (19): e6826. doi: 10.1097/MD.0000000000006826
  9. Мухарлямов Н.М., Саттбеков Ж.С., Сучков В.В. Системная артериальная гипертензия у больных хроническими неспецифическими заболеваниями легких. Кардиология. 1974; 34 (12): 55-61.
  10. Задионченко В.С., Адашева Т.В. Шилова Е.В. и др. Клинико-функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. РМЖ. 2003; 9: 535.
  11. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.
  12. Напалков Д.А., Панферов А.С. Особенности течения сердечно-сосудистых заболеваний и принципы выбора рациональной антигипертензивной терапии у больных хронической обструктивной болезнью легких. Системные гипертензии. 2013; 3: 77-9
  13. Melot C, Hallemans R, Naeije R et al. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130 (4): 612-6.
  14. Dicpinigaitis P.V, Thomas S.A, Sherman M.B et al. Losartan-induced bronchospasm. J Allergy Clin Immunol 1996; 98 (6 Pt 1): 1128-30.
  15. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715-25.
  16. Kazani S, Israel E. Treatment with beta blockers in people with COPD. BMJ 2011; 342: d2655. doi: 10.1136/bmj.d2655
  17. Ponikowski P, Voors A.A, Anker S.D et al. ESC Scientific Document Group. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Рос. кардиологический журн. 2017; 1 (141): 7-81
  18. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Общество специалистов по сердечной недостаточности. Российское кардиологическое общество. М., 2016.
  19. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 г., на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 г. Сердечная недостаточность. 2013; 14 (7): 379-472
  20. McMurray J.J, Adamopoulos S, Anker S.D. et al. ESC Committee for Practice Guidelines. Рекомендации Европейского общества кардиологов (EOK) по диагностике и лечению острой и хронической сердечной недостаточности 2012 г. Рос. кардиологический журн. 2012; 4 (102), Прил. 3.
  21. Le Jemtel T.H, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. Am J Coll Cardiol 2007; 49 (2): 171-80.
  22. Garcia-Rodriguez L.A, Wallander M.A, Martin-Merino E, Johansson S. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med 2010; 104 (11): 1691-9.
  23. Franssen F.M, Rochester C.L. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev 2014; 23 (131): 131-41.
  24. Rutten F.H, Cramer M.J, Grobbee D.E et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26 (18): 1887-94.
  25. Smith M.C, Wrobel J.P. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 871-88. doi: 10.2147/COPD.S49621
  26. Halpin D.M, Decramer M, Celli B et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT(R) trial. Lung 2011; 189 (4): 261-8.
  27. Miller J, Edwards L.D, Agustí A et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107 (9): 1376-84. doi: 10.1016/j.rmed.2013.05.001
  28. Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Часть I. ХОБЛ и поражения сердечно-сосудистой системы. РМЖ. 2008; 10: 58-65
  29. Kleiger R.E, Senior R.M. Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest 1974; 65 (5): 483-7.
  30. Задионченко В.С. и др. Нарушения ритма сердца у больных хроническими обструктивными болезнями легких. Пульмонология. 2003; 6: 88-99.
  31. Fuso L, Incalzi R.A, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98 (3): 272-7.
  32. Ревишвили А.Ш., Рзаев Ф.Г., Горев М.В., Нардая Ш.Г. Клинические рекомендации «Фибрилляция предсердий». Рекомендации Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и электрокардиостимуляции (ВНОА), Российского кардиологического общества (РКО) и Ассоциации сердечно-сосудистых хирургов России (АССХ). 2017.
  33. Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50 (5): e1-e88.
  34. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip G.Y. et al. Рекомендации по диагностике и лечению фибрилляции предсердий 2010. Рабочая группа Европейского общества кардиологов (ESC). Рациональная фармакотерапия в кардиологии. 2011 (Прил. к №1-2
  35. Сулимов В.А., Голицын С.П., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. М., 2012
  36. Curkendall S.M, DeLuise C, Jones J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (1): 63-70.
  37. Авдеев С.Н., Баймаканова Г.Е. Сердечно-сосудистые заболевания у больных ХОБЛ: проблема выбора лекарственных препаратов. Атмосфера. Пульмонология и аллергология. 2008; 2: 3-8.]
  38. Hole D.J, Watt G.C, Davey-Smith G. et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ : Br Med J 1996; 313 (7059): 711-6.
  39. Sin D.D, Wu L, Anderson J.A et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60 (12): 992-7.
  40. McAllister D.A, Maclay J.D, Mills N.L. et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176 (12): 1208-14.
  41. Eickhoff P, Valipour A, Kiss D. et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178 (12): 1211-8.
  42. Thomsen M, Dahl M, Lange P. et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (10): 982-8.
  43. Cote C.G, Casanova C, Marín J.M et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008; 31 (3): 571-8.
  44. Divo M, Cote C, de Torres J.P. et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (2): 155-61. doi: 10.1164/rccm.201201-0034OC
  45. Brekke P.H, Omland T, Smith P, Soyseth V. Underdiagnosis of myocardial infarction in COPD: Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008; 102 (9): 1243-7.
  46. Chang C.L, Robinson S.C, Mills G.D et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66 (9): 764-8. doi: 10.1136/thx.2010.155333
  47. Ibanez B, James S, Agewall S et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (2): 119-77. doi: 10.1093/eurheartj/ehx393
  48. Roffi M, Patrono C, Collet J.P et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016 ; 37 (3): 267-315. doi: 10.1093/eurheartj/ehv320
  49. Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949-3003. doi: 10.1093/eurheartj/eht296

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies